Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

FDA Experts Weigh In On Incannex’s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

By Jelena Martinovic
May 7, 12:35 PM
Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.

IXHL

Read More
4 minute read

Psyched: Suggestibility And Psychedelics’ Effects, EU’s $7M Research Fund, Australia’s Treatment Delivery, BZ Podcast And More

By Lara Goldstein
January 27, 11:00 AM
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian psychiatrists provide first psychedelic-assisted treatments in 50 years.

ATAI